Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases

A product, mediated technology, applied in the field of dairy ingredients and dairy products for the treatment and/or prevention of COX-2 mediated diseases, capable of solving problems such as side effects

Inactive Publication Date: 2010-06-09
NESTEC SA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, NSAIDs are known to have serious side effects such as kidney problems and duodenal and gastric ulcers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases
  • Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases
  • Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Milk sample preparation

[0069] Standard procedures for the preparation of dairy ingredients were carried out as described in C. Alais, Science du Lait, Principles Techniques Laitieres. SEPAIC, Paris, 4th Edition, 1984, pp. 29-35 and 159-178, unless expressly stated.

[0070] The described laboratory-scale fractionation procedure was developed from traditional industrial dairy processing methods. Surprisingly, the selection and separation efficiency can be significantly increased by carrying out the method steps described below, in particular performing high-acceleration centrifugation and particularly modified washing steps.

[0071] 1.1 milk

[0072] Milk was purchased from a local market ("Toni lait", Switzerland).

[0073] In the first step, cream is extracted from whole milk by centrifugation at accelerations up to 13 600 g (9 000 rpm for 30 min) using a fixed-angle rotor, Sorval GS3. Starting from 2.200ml of whole milk, 90g of cream is recovered from the t...

Embodiment 2

[0119] Subfractionation of Soluble Whey Proteins in Bovine Milk

[0120] Melt 15ml of the soluble whey protein obtained as described in Example 1 in a 37°C water bath for 20 minutes, shake and mix, and centrifuge in a 5415 Eppendorf centrifuge at 13.000rpm for 1 minute. After filtering with a 0.45 μm Millipore filter (306 / GSWP04700.GS), 10 ml of the product was injected into an HR16×50 column filled with 100 ml of Source 15RPC TN 17-0727-02 (polystyrene-divinylbenzene). The column was connected to an FPLC system controlled by a UNICORN workstation (AmershamPharmacia Biotech).

[0121] Chromatography conditions are:

[0122] Buffer A: 0.1% TFA in water (2000ml of miliQ water filtered by a 0.45μm Millipore system, plus 2ml of TFA (Sigma 91699, 100ml));

[0123] Buffer B: 80% acetonitrile, 0.85% TFA (400ml miliQ water filtered by 0.45μm Millipore system, add 1.600ml acetonitrile, degas in ultrasonic bath for 15 minutes, and finally make up 1.7ml TFA).

[0124]The column was ...

Embodiment 3

[0135] COX-2 screening

[0136] 2.1 Materials and methods

[0137] HUV-EC-C cells (immortalized endothelial cell line derived from normal human umbilical cord vessels; ATCC CRL1730; M.Miralpeix, M.Camacho et al., "British Journal of Pharmacology" (Brit.J.Pharmacol.) 121( 1997), 171-180) were inoculated onto a 96-well plate (PRMI 1640+10% FCS), and treated with 100nM (nmol / l) phorbol 12-myristoyl 13-acetate at 37°C for 6 hours, To induce COX-2 isozyme. Subsequently, 50 μM (μmol / l) arachidic acid was added, and the cells were incubated at 37°C for 30 minutes in the presence of the test compound or mixture. ), radioactivity was determined by scintillation counter (Topcount, Packard).

[0138] The results obtained are expressed as percent of the control value and percent inhibition of the control value in the presence of the test compound. The control value is the concentration of HUV-EC-C cells stimulated with phorbol myristoyl acetate (PMA) (or alpha tumor necrosis facto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to nutritional and pharmaceutical compositions for treating and preventing cyclooxygenase-2 mediated diseases and to a process for increasing the cyclooxygenase-2 inhibiting activity of a product. In addition thereto, the present invention relates to the use of one ore more milk protein fractions and / or one ore more milk protein preparations for inhibiting the activity of cyclooxygenase-2 (COX-2), in particular for the preparation of a medicament or a functional food for treating and preventing cyclooxygenase-2 mediated diseases.

Description

field of invention [0001] The present invention relates to a nutritional and pharmaceutical composition for the treatment and / or prevention of cyclooxygenase-2 mediated diseases, and a method for increasing the cyclooxygenase-2 inhibitory activity of the product. In particular, the present invention also relates to the use of one or more milk protein ingredients and / or one or more milk protein products for inhibiting the activity of cyclooxygenase-2, especially in the preparation of Use in food or medicine for cyclooxygenase-2 mediated diseases. technical background [0002] Cyclooxygenase (COX) is a key enzyme required for the conversion of arachidonic acid into prostaglandins (PGs). Two isoforms of COX have been identified so far, COX-1 and COX-2, which differ in many respects: COX-1 is constitutively expressed in most tissues and is presumed to be responsible for the production of prostaglandins, Prostaglandins control normal physiological functions, such as maintaining...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A23L1/305A61K38/00A23J1/20A61K35/20
CPCA23V2002/00A61K35/20A23J1/202A61K38/005A23J1/205A23L1/3056A23L33/19A61P1/02A61P15/08A61P19/02A61P25/04A61P25/28A61P29/00A61P31/12A61P31/16A61P35/00A61P43/00A23V2250/54252A23V2200/308
Inventor L·博韦托J·奥C·梅斯
Owner NESTEC SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com